BACKGROUND: Ovarian cancer (OC) is a highly aggressive malignancy in the reproductive system of women, with a high recurrence rate. The present research was designed to establish a relapse-based RiskScore model to assess the drug sensitivity and prognosis for patients with OC. METHODS: Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases were accessed to obtain relevant sample data. The single-cell atlas of primary and relapse OC was characterized using the "Seurat" package. Differentially expressed genes (DEGs) between primary and relapse samples were identified by FindMarkers function. Subsequently, univariate Cox, least absolute shrinkage and selection operator (LASSO) and stepwise regression analysis were employed to determine independent prognostic genes related to relapse in OC to establish a RiskScore model. Applying "timeROC" package, the predictive performance of RiskScore model was assessed. Drug sensitivity of different risk groups was evaluated using "pRRophetic" package. The effects of relapse-related prognostic genes on OC cells were detected with in vitro assays. RESULTS: The single-cell atlas revealed that compared to primary OC, fibroblasts were reduced but epithelial cells were increased in relapse OC. Five prognostic genes (LDHA, NOP58, NMU, KRT19, and RPS23) independently linked to relapse in OC were identified to construct a RiskScore model, which showed high robustness in the prognostic prediction for OC patients. High-risk group tended to have worse outcomes in terms of different clinical features than the low-risk group. Further, six drugs (Vinorelbine, GW-2580, S-Trityl-L-cysteine, BI-2536, CP466722, NSC-87877) were found to be correlated with the RiskScore. While the high-risk group had higher IC(50) values to these drugs, the low-risk group was more sensitive to the six drugs. In addition, KRT19 silencing markedly inhibited the invasion and migration of OC cells. CONCLUSION: This study established a relapse-related RiskScore model based on five prognostic genes (LDHA, NOP58, NMU, KRT19, and RPS23), offering novel insights into the recurrence mechanisms in OC and contributing to the development of individualized treatment strategies.
Development of a relapse-related RiskScore model to predict the drug sensitivity and prognosis for patients with ovarian cancer.
开发复发相关风险评分模型,以预测卵巢癌患者的药物敏感性和预后
阅读:3
作者:Jin Zhixin, Wang Xuegu, Li Xiang, Yang Shasha, Ding Biao, Fei Jiaojiao, Wang Xiaojing, Dou Chengli
| 期刊: | PeerJ | 影响因子: | 2.400 |
| 时间: | 2025 | 起止号: | 2025 Aug 11; 13:e19764 |
| doi: | 10.7717/peerj.19764 | 研究方向: | 肿瘤 |
| 疾病类型: | 卵巢癌 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
